937636-24-3Relevant academic research and scientific papers
Hybrid compounds as new Bcr/Abl inhibitors
Wang, Deping,Zhang, Zhang,Lu, Xiaoyun,Feng, Yubing,Luo, Kun,Gan, Jirong,Yingxue, Liu,Wan, Junting,Li, Xiang,Zhang, Fengxiang,Tu, Zhengchao,Cai, Qian,Ren, Xiaomei,Ding, Ke
, p. 1965 - 1968 (2011)
A series of 2,4-disubstituted thiazole derivatives were designed and synthesized as new Bcr/Abl inhibitors by hybriding the structural moieties from FDA approved imatinib, nilotinib and dasatinib. The new inhibitors strongly suppressed the activity of Bcr/Abl kinase and potently inhibited the proliferation of K562 and KU812 leukemia cancer cells. Compound 4i displayed comparable potency with that of nilotinib in both biochemical kinase assay and cancer cell growth inhibition assay. These inhibitors might serve as lead compounds for further developing new anticancer drugs.
